<DOC>
	<DOC>NCT00757770</DOC>
	<brief_summary>The purpose of this study is to evaluate the lot-to-lot consistency of three production lots of GSK Biologicals' HRV vaccine in terms of immunogenicity and safety in healthy infants aged 2 months at the time of first vaccination.</brief_summary>
	<brief_title>Assessment of Clinical Consistency of Three Production Lots of GSK Biologicals' HRV Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study. A male or female between, and including, 6 and 12 weeks of age at the time of the first vaccination. Written informed consent obtained from the parent or guardian of the subject. Free of obvious health problems as established by medical history and clinical examination before entering into the study. Use of any investigational or nonregistered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. Child is unlikely to remain in the study area for the duration of the study. Previous confirmed occurrence of rotavirus gastroenteritis. Gastroenteritis within 7 days preceding the study vaccine administration. Household contact with an immunosuppressed individual or pregnant woman. Use of antibiotics during the period starting from 7 days before dose 1 of vaccine(s). Planned administration of a vaccine (other than routine pediatric vaccines) not foreseen by the study protocol during the period starting from 14 days before each dose of study vaccine(s) and ending 14 days after. Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection. Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract or other serious medical condition as determined by the investigator. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Major congenital defects or serious chronic illness. Acute disease at time of enrollment. Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Gastroenteritis</keyword>
</DOC>